<DOC>
	<DOC>NCT02567955</DOC>
	<brief_summary>A ninevalent HPV vaccine (Gardasil-9) has been recently approved for clinical use. No data on immunogenicity and safety of interchangeable use of the ninevalent and the bivalent vaccine (Cervarix) are available. The main objective of this study is to assess the immunogenicity of ninevalent and bivalent HPV vaccines when administered to 9-10-year-old girls and boys according to 0-6 month schedule.</brief_summary>
	<brief_title>Immunogenicity and Safety of Gardasil-9 and Cervarix</brief_title>
	<detailed_description>The proportion of subjects with detectable antibodies and antibody geometrical mean titers to 9 HPV genotypes included in the Gardasil-9 vaccine will be assessed 1 and 6 months post-first dose and 1, 18 and 36 months post-second dose of vaccine.</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>910yearold girls and boys previously received an HPV vaccine immunosuppressed known allergy to a vaccine component</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>HPV vaccines, interchangeable use</keyword>
</DOC>